- EMVision Medical Devices (EMV) has received firm results from a clinical trial testing its novel imaging brain scanner technology
- The study collected data from 30 stroke patients to guide improvements to EMVision’s technology
- Pleasingly, the trial showed the brain scanner device could classify the stroke type with an accuracy of between 93.3 and 96 per cent
- Additionally, fusion methodology produced encouraging results
- Fusion imaging collects data and signals from each algorithm to create one compact image to refer to
- EMVision’s device also received positive feedback from operators and patients
- The company will use the data to accelerate product development and future clinical studies and discussions
- Company shares have dropped a slight 1.41 per cent to trade for $2.80
EMVision Medical Devices (EMV) has posted strong results for a pilot clinical trial testing its novel imaging brain scanner technology.
The study was conducted at the Princess Alexandra Hospital (PAH) in Brisbane. EMVision collated data from 30 patients diagnosed with ischaemic or haemorrhagic stroke to guide improvements to the EMVision device.
From the 30 patients, 19 only had a CT scan performed, whereas 11 had both a CT and MRI scan done. As a result, 30 per cent of the patients were diagnosed as having had a haemorrhagic stroke and 70 per cent as having had an ischaemic stroke.
The trial showed the brain scanner device was able to classify the stroke type with an overall accuracy of between 93.3 and 96 per cent.
The device also confirmed it can localise targets in the correct quadrant with an overall accuracy of between 86.7 and 96 per cent.
“We are delighted by these results which indicate that we are able to discriminate and localise haemorrhagic and ischaemic strokes with an encouraging degree of accuracy under these conditions. We have exceeded our original objectives for this study,” CEO Dr Ron Weinberger said.
Fusion methodology, which leverages data from multiple algorithms, produced encouraging results. Image fusion involves collecting data points and signal intensities from each algorithm to produce one image.
EMVision’s brain scanner device received positive feedback from operators and patients saying they either agreed or strongly agreed with various aspects of the device and its efficiency.
“The latest results are exciting in showing excellent discrimination between ischaemic stroke and haemorrhage in the data collected to date,” EMVision Clinical Advisor and Stroke Neurologist Professor Michael O’Sullivan said.
“The value of combining multiple algorithms in a fusion approach is also an
emerging theme, which could help to tailor the approach to the setting and clinical question,” he added.
EMVision believes it has enough information from the study to continue accelerating product development as well as future clinical studies and discussions with potential partners.
Company shares have dropped a slight 1.41 per cent to trade for $2.80 at $12.57 pm AEDT.